MicroRNAs in pulmonary arterial hypertension: pathogenesis,
diagnosis and treatment

J 2015

MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment

BIENERTOVÁ VAŠKŮ, Julie; Jan NOVÁK a Anna VAŠKŮ

Základní údaje

Originální název

MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment

Autoři

BIENERTOVÁ VAŠKŮ, Julie; Jan NOVÁK a Anna VAŠKŮ

Vydání

Journal of the American Society of Hypertension, New York, Elsevier Science Inc. 2015, 1933-1711

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30000 3. Medical and Health Sciences

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.656

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/15:00083305

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

Hypoxia; lungs; non-coding RNAs; vascular remodeling

Štítky

EL OK

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 31. 7. 2015 15:46, Ing. Mgr. Věra Pospíšilíková

Anotace

V originále

Pulmonary arterial hypertension (PAH) is a severe and increasingly prevalent disease, manifested by the maladaptation of pulmonary vasculature, which consequently leads to right heart failure and possibly even death. The development of PAH is characterized by specific functional as well as structural changes, primarily associated with the aberrant function of the pulmonary artery endothelial cells, smooth muscle cells, and vascular fibroblasts. MicroRNAs constitute a class of small 22–nucleotides–long non–coding RNAs that post–transcriptionally regulate gene expression and that may lead to significant cell proteome changes. While the involvement of miRNAs in the development of various diseases—especially cancer—has been reported, numerous miRNAs have also been associated with PAH onset, progression, or treatment responsiveness. This review focuses on the role of microRNAs in the development of PAH as well as on their potential use as biomarkers and therapeutic tools in both experimental PAH models and in humans. Special attention is given to the roles of miR–21, miR–27a, the miR–17–92 cluster, miR–124, miR–138, the miR–143/145 cluster, miR–150, miR–190, miR–204, miR–206, miR–210, miR–328, and the miR–424/503 cluster, specifically with the objective of providing greater insight into the pervasive roles of miRNAs in the pathogenesis of this deadly condition.

Citovat

BIENERTOVÁ VAŠKŮ, Julie; Jan NOVÁK a Anna VAŠKŮ. MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment. Journal of the American Society of Hypertension. New York: Elsevier Science Inc., 2015, roč. 9, č. 3, s. 221-234. ISSN 1933-1711. Dostupné z: https://doi.org/10.1016/j.jash.2014.12.011.

@article{1305259,
   author = {Bienertová Vašků, Julie and Novák, Jan and Vašků, Anna},
   article_location = {New York},
   article_number = {3},
   doi = {https://doi.org/10.1016/j.jash.2014.12.011},
   keywords = {Hypoxia; lungs; non-coding RNAs; vascular remodeling},
   language = {eng},
   issn = {1933-1711},
   journal = {Journal of the American Society of Hypertension},
   title = {MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment},
   url = {http://www.ashjournal.com/article/S1933-1711(14)00909-7/abstract},
   volume = {9},
   year = {2015}
}

TY  - JOUR
ID  - 1305259
AU  - Bienertová Vašků, Julie - Novák, Jan - Vašků, Anna
PY  - 2015
TI  - MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment
JF  - Journal of the American Society of Hypertension
VL  - 9
IS  - 3
SP  - 221-234
EP  - 221-234
PB  - Elsevier Science Inc.
SN  - 19331711
KW  - Hypoxia
KW  - lungs
KW  - non-coding RNAs
KW  - vascular remodeling
UR  - http://www.ashjournal.com/article/S1933-1711(14)00909-7/abstract
L2  - http://www.ashjournal.com/article/S1933-1711(14)00909-7/abstract
N2  - Pulmonary arterial hypertension (PAH) is a severe and increasingly prevalent disease, manifested by the maladaptation of pulmonary vasculature, which consequently leads to right heart failure and possibly even death. The development of PAH is characterized by specific functional as well as structural changes, primarily associated with the aberrant function of the pulmonary artery endothelial cells, smooth muscle cells, and vascular fibroblasts. MicroRNAs constitute a class of small 22–nucleotides–long non–coding RNAs that post–transcriptionally regulate gene expression and that may lead to significant cell proteome changes. While the involvement of miRNAs in the development of various diseases—especially cancer—has been reported, numerous miRNAs have also been associated with PAH onset, progression, or treatment responsiveness. This review focuses on the role of microRNAs in the development of PAH as well as on their potential use as biomarkers and therapeutic tools in both experimental PAH models and in humans. Special attention is given to the roles of miR–21, miR–27a, the miR–17–92 cluster, miR–124, miR–138, the miR–143/145 cluster, miR–150, miR–190, miR–204, miR–206, miR–210, miR–328, and the miR–424/503 cluster, specifically with the objective of providing greater insight into the pervasive roles of miRNAs in the pathogenesis of this deadly condition.
ER  -

BIENERTOVÁ VAŠKŮ, Julie; Jan NOVÁK a Anna VAŠKŮ. MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment. \textit{Journal of the American Society of Hypertension}. New York: Elsevier Science Inc., 2015, roč.~9, č.~3, s.~221-234. ISSN~1933-1711. Dostupné z: https://doi.org/10.1016/j.jash.2014.12.011.

Přehled o publikaci